Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kasey Hollandsworth

Physician Assistant Tucson, AZ Physician Assistant

NPI 1356894554 CMS profile 11166697

1595 E River Rd Ste 201, Tucson, AZ 85718

Open in the dashboard

General payments

$6,021

309 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kasey Hollandsworth of Tucson, AZ is reported in the CMS Open Payments database as having received $6,021 across 309 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,083 117
2024 General $1,430 72
2023 General $689 45
2022 General $748 24
2021 General $1,071 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kasey Hollandsworth
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kasey Hollandsworth were reported at $2,083. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kasey Hollandsworth Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,071 $132 $37–$438 $132
2022 $748 $155 $48–$522 $149
2023 $689 $167 $52–$557 $160
2024 $1,430 $178 $55–$600 $164
2025 $2,083 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,891 114 payments
  2. Janssen Biotech, Inc. $778 57 payments
  3. Genzyme Corporation $590 28 payments
  4. Galderma Laboratories, L.P. $289 20 payments
  5. Novartis Pharmaceuticals Corporation $281 13 payments
  6. Incyte Corporation $259 11 payments
  7. Regeneron Healthcare Solutions, Inc. $233 7 payments
  8. Sanofi-Aventis U.S. LLC $195 2 payments
  9. UCB, Inc. $191 8 payments
  10. LEO Pharma Inc. $174 7 payments
  11. Other $1,140 42 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,644 304 payments
  2. Education $376 5 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT $1,098 43 payments
  2. SKYRIZI Immunology $1,016 54 payments
  3. TREMFYA $672 42 payments
  4. SKYRIZI Immunology $434 38 payments
  5. OPZELURA $259 11 payments
  6. HUMIRA $255 13 payments
  7. NEMLUVIO $233 15 payments
  8. RINVOQ $222 12 payments
  9. SIMPONI ARIA $210 17 payments
  10. STELARA $210 17 payments
  11. Other $2,381 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

904

Median for Physician Assistant: 241

Drug cost

$199,976

Median for Physician Assistant: $4,110

Branded share of claims

6.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 42 $173,597
Fluorouracil Generic 79 $5,855
Clobetasol Propionate Generic 86 $4,249
Tacrolimus Generic 29 $3,585
Metronidazole Generic 53 $2,664
Ketoconazole Generic 159 $2,534
Triamcinolone Acetonide Generic 179 $1,610
Clindamycin Phosphate Generic 49 $1,385
Ciclopirox Generic 40 $1,144
Fluocinonide Generic 39 $1,121

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$107,416

Of which drugs: $1,884

Medicare patients

695

Average age 74

Services billed

3,089

455 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 40%
Ischemic heart disease 19%
Osteoporosis 18%
Diabetes 17%
Depression 17%
Chronic kidney disease 16%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 41 $22

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $441
$441 — —
TREMFYA
  • Janssen Biotech, Inc. $234
$234 — —
RINVOQ
  • AbbVie, Inc. $128
$128 — —
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $95
  • GENZYME CORPORATION $30
$125 42 —
VTAMA
  • Dermavant Sciences, Inc. $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

309 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record